

DAFTAR PUSTAKA

- Al-Qur'an dan Terjemahnya* 2002. Departemen Agama RI, Jakarta.
- Akbar A 1988. *Etika Kedokteran dalam Islam*. Pustaka Antara, Jakarta.
- Barbare JC, et al 2005. Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma. *J. Clin. Oncol.* 23, 4338-4346.
- Budihusodo U 2009. Karsinoma Hati, dalam *Ilmu Penyakit Dalam* (Sudoyo, et al., eds) Edisi 5. Interna Publishing, Jakarta.
- Cheng AL, et al 2009. Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-blind, Placebo-controlled Trial. *Lancet. Oncol.* 10, 25-34.
- Curley S 2004. Radiofrequency Ablation of Hepatocellular Carcinoma, dalam *Radiofrequency Ablation for Cancer – Current Indications, Techniques, and Outcomes* (Ellis LM, et al., eds.) Edisi 1. Springer Verlag, New York.
- Dancygier H 2010. Hepatocellular Carcinoma, dalam *Clinical Hepatology – Principles and Practice of Hepatobiliary Diseases* (Dancygier H., ed.) Edisi 1. Springer Verlag, Berlin.
- Delbeke D dan Walker RC 2010. Hepatobiliary and Pancreatic Malignancies, dalam *Hibrid PET/CT and SPECT/CT Imaging – A Teaching File* (Delbeke D. dan Israel O., eds.). Springer, New York.
- Fasel JHD, et al 2007. Macroscopic Anatomy of The Liver, dalam *Macroscopic Anatomy of The Liver. Textbook of Hepatology* (Rodès J. et al., eds) Edisi 3. Blackwell Publishing Ltd, Massachusetts.
- Forner A, Llovet JM dan Bruix J 2012. Hepatocellular Carcinoma. *Lancet. Oncol.* 379, 1245–1255.
- Fukumoto T 2011. *Induction Chemotherapy for Hepatocellular Carcinoma*, dalam *Induction Chemotherapy – Integrated Treatment Programs for Locally Advanced Cancers* (Aigner KR. dan Stephens FO., eds). Springer Verlag, Berlin.
- Fung KTT, et al 2004. Systematic Review of Radiological Imaging for Hepatocellular Carcinoma in Cirrhotic Patients. *J. Brit. Radiol.* 77, 633–640.

Hanafiah dan Jusuf M 2008. *Etika Kedokteran dan Ajaran Islam*. Pustaka Bangsa Press, Medan.

Ho CL, et al 2003. ¹¹C-Acetate PET Imaging in Hepatocellular Carcinoma and Other Liver Mass. *J. Nucl. Med.* 44, 213-21.

Kulik LM, et al 2008. Safety and Efficacy of ⁹⁰Y Radiotherapy for Hepatocellular Carcinoma With and Without Portal Vein Thrombosis. *J. Hep.* 47, 71-81.

Kuntz E 2008. Morphology of the Liver, dalam *Morphology of the Liver. Hepatology Textbook and Atlas* (Kuntz E., ed.) Edisi 3. Springer Medizin Verlag, Berlin.

Lee WC dan Chen MF 2010. Epidemiology, Etiology, and Natural History of Hepatocellular Carcinoma, dalam *Epidemiology, Etiology and Natural History of Hepatocellular Carcinoma* (Clavien P.A., et al., eds). Blackwell Publishing Ltd, Chichester.

Leong TYM 2008. Epidemiology, dalam *A Book on Hepatocellular Carcinoma* (Lau W.Y., ed) Edisi 1. World Scientific Publishing Co. Pte. Ltd, Singapore.

Li CX, et al 2004. Analysis of clinical effect of high-intensity focused ultrasound on livercancer. *World. J. Gastroenterol.* 10, 2201-2204.

Liu CH, et al 2009. Diagnostic Imaging Pre- and Post-ablation, dalam *Interventional Radiological Treatment of Liver Tumors* (Adam A. dan Mueller P.R., eds) Edisi 1. Cambridge University Press, Cambridge.

Llovet JM et al 2008. SHARP investigators study group, sorafenib in advanced hepatocellular carcinoma. *N. Engl. J. Med.* 359, 378-390.

Rifai A 1996. Fisiologi dan Biokimia Hati, dalam *Buku ajar Ilmu Penyakit Dalam Jilid 1* (Rifai A., ed) Edisi 3. Balai Penerbit FKUI, Jakarta.

Rimassa L dan Santoro A 2009. Sorafenib therapy in advanced hepatocellular carcinoma : the SHARP trial. *J. Expert Rev. Anticancer Ther.* 9, 739-745.

Roberts LR 2009. Hepatocellular Carcinoma, dalam *Textbook of Gastroenterology* (Yamada T., et al, eds) Edisi 5. Blackwell Publishing Ltd, Chichester.

Singgih B dan Datau EA 2006. *Hepatoma dan Sindrom Hepatorenal*. Cermin Dunia Kedokteran, Jakarta.

- Su'dan 1997. *Al Qur'an dan Panduan Kesehatan Masyarakat*. Dana Bhakti Prima Yasa, Yogyakarta.
- Taha A 1992. *Kedokteran Islam*. Percetakan Dewan Bahasa dan Pustaka, Selangor.
- Thabut D, et al 2011. Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. *J. Hep.* 54, 573–585
- Wang XW, et al 2011. Biology of Hepatocellular Carcinoma: Past, Present and Beyond, dalam *Molecular Genetics of Liver Neoplasia* (Wang X.W., et al, eds). Springer, New York.
- Wasmuth JC 2010. Hepatitis B – Epidemiology, -Transmission and Natural History, dalam *Hepatology – A Clinical Textbook* (Mauss S., et al, eds) Edisi 2. Flying Publisher, Düsseldorf.
- Weishaupt D 2010. Modalities for Imaging Liver Tumors, dalam *Malignant Liver Tumors* (Clavien P.A., et al, eds) Edisi 3. Blackwell Publishing Ltd, Chichester.
- White DL, et al 2010. Epidemiology of Hepatocellular Carcinoma, dalam *Hepatocellular Carcinoma Diagnosis and Treatment* (Carr B.I. ed) Edisi 2. Humana Press, New York.
- Wilhelm SM, et al 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. *Mol. Cancer. Ther.* 7, 3129-3140.
- Wu F, et al 2005. Advanced Hepatocellular Carcinoma: Treatment with High-Intensity Focused Ultrasound Ablation Combined with Transcatheter Arterial Embolization. *J. Radiol.* 235, 659–667
- Xie B, David HW, Stuart JS 2012. Sorafenib for Treatment of Hepatocellular Carcinoma : A Systematic Review. *Dig. Dis. Sci.* 57, 1122-1129
- Zhu AX, et al 2005. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular Carcinoma. *J. Oncol.* 10, 392–398
- Zuhroni 2003. *Islam untuk disiplin ilmu kesehatan dan kedokteran*. Departemen Agama RI Direktorat Jenderal Kelembagaan Agama Islam, Jakarta.